Zacks Research Has Negative Outlook of DNLI FY2024 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Analysts at Zacks Research reduced their FY2024 EPS estimates for Denali Therapeutics in a research note issued to investors on Tuesday, January 28th. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings per share of ($2.77) for the year, down from their previous forecast of ($2.71). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.51) EPS.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period last year, the company earned ($0.72) earnings per share.

Other analysts also recently issued research reports about the stock. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research note on Monday, December 16th. HC Wainwright reduced their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $23.30 on Friday. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.33. The business’s fifty day moving average is $22.42 and its 200 day moving average is $24.83. The stock has a market capitalization of $3.35 billion, a PE ratio of -8.44 and a beta of 1.39.

Insider Activity

In related news, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. This trade represents a 10.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,518 shares of company stock valued at $1,469,382 in the last ninety days. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. State of New Jersey Common Pension Fund D grew its holdings in shares of Denali Therapeutics by 11.3% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 86,243 shares of the company’s stock valued at $1,758,000 after purchasing an additional 8,760 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Denali Therapeutics by 0.3% in the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company’s stock worth $3,880,000 after buying an additional 497 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Denali Therapeutics in the 4th quarter worth about $379,000. abrdn plc raised its position in shares of Denali Therapeutics by 10.6% during the 4th quarter. abrdn plc now owns 402,282 shares of the company’s stock valued at $8,199,000 after buying an additional 38,603 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,517 shares of the company’s stock valued at $622,000 after acquiring an additional 2,982 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.